Greece is set to introduce a significant advancement in its healthcare system by launching a home delivery service for specialized, high-cost medicines, designed for patients battling chronic or serious illnesses. Prime Minister Kyriakos Mitsotakis announced on Friday that this new initiative will commence on June 16. He described the development as a key step toward improving the quality of care and upholding the dignity of vulnerable patients who require these critical treatments.

During the official launch of the service by the state-run health insurer EOPYY, Prime Minister Mitsotakis remarked, “It is an important and moving day.” He emphasized that the program addresses “a long-standing demand for the self-evident right to dignity and care from the state is becoming a reality.” The home delivery program will be executed through a partnership between EOPYY and a certified private distributor. Its primary target demographic includes patients who face mobility limitations or other significant health challenges that hinder their ability to access necessary medications.

The range of medicines covered by this new home delivery service is extensive, encompassing critical pharmaceuticals such as oncology drugs, immunosuppressive medications, biological agents, and other specialized drugs. These medications are typically used in the treatment of rare diseases or persistent chronic conditions, highlighting the program's focus on patients with complex medical needs. By delivering these medicines directly to patients' homes, the initiative aims to alleviate logistical burdens and ensure timely access to treatment.

Prime Minister Mitsotakis assured the public that comprehensive planning had been undertaken to ensure the smooth rollout and effectiveness of the new delivery system. He urged citizens to trust the service, underscoring the government's commitment to its success. Additionally, Mitsotakis expressed his gratitude towards patient associations for their continuous and valuable input during the development phase. He referred to these associations as “institutional interlocutors,” acknowledging their vital role in shaping healthcare policies by providing insights derived from their first-hand knowledge of patient needs and healthcare system challenges.